Actuate Therapeutics, Inc. financial data

Symbol
ACTU on Nasdaq
Location
1751 River Run, Suite 400, Fort Worth, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 112 %
Debt-to-equity 1.07K %
Return On Equity -2.92K % -8228%
Return On Assets -251 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.2M shares +19%
Common Stock, Shares, Outstanding 23.2M shares +19%
Common Stock, Value, Issued 23 USD +15%
Weighted Average Number of Shares Outstanding, Basic 21.4M shares +98.6%
Weighted Average Number of Shares Outstanding, Diluted 21.4M shares +98.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.8M USD -42%
General and Administrative Expense 12.5M USD +101%
Operating Income (Loss) -24.4M USD -1.47%
Nonoperating Income (Expense) 246K USD
Net Income (Loss) Attributable to Parent -24.1M USD +15.2%
Earnings Per Share, Basic 6 USD/shares +54.5%
Earnings Per Share, Diluted 6 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.9M USD +25.2%
Assets, Current 17.4M USD +22.3%
Other Assets, Noncurrent 270K USD
Assets 17.7M USD +24.2%
Accounts Payable, Current 1.25M USD -46.6%
Liabilities, Current 6.37M USD -25%
Liabilities 6.78M USD -23.9%
Retained Earnings (Accumulated Deficit) -150M USD -19.2%
Stockholders' Equity Attributable to Parent 10.9M USD +104%
Liabilities and Equity 17.7M USD +24.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.62M USD +12%
Net Cash Provided by (Used in) Financing Activities -133K USD -103%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 23.2M shares +19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.9M USD +25.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 37.7M USD +18.8%
Deferred Tax Assets, Gross 37.7M USD +18.8%
Deferred Tax Assets, Operating Loss Carryforwards 14.3M USD +14.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 161M USD +22.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 5.7M USD +218%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%